Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | CISD2 | Q8N5K1 | 15/20 | 0.80 |
| ▸ | RAB9A | P51151 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 1/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.70 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.70 |
| ▸ | RELA | Q04206 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20838917 | 0.91 | CISD2 (0.84) | ADORA1CISD2RAB9AALDH1A1NPC1 | |
| SCHEMBL20852896 | 0.89 | ADORA1 (0.80) | ADORA1CISD2RAB9AALDH1A1NPC1 | |
| SCHEMBL20838881 | 0.89 | ADORA1 (0.80) | ADORA1CISD2RAB9AALDH1A1NPC1 | |
| SCHEMBL25106705 | 0.89 | CISD2 (1.00) | ADORA1CISD2RAB9AALDH1A1NPC1 | |
| SCHEMBL20838879 | 0.86 | CISD2 (0.81) | ADORA1CISD2RAB9AALDH1A1NPC1 | |
| SCHEMBL20838894 | 0.86 | CISD2 (0.81) | ADORA1CISD2RAB9AALDH1A1NPC1 | |
| SCHEMBL20853081 | 0.84 | CISD2 (0.73) | ADORA1CISD2RAB9AALDH1A1NPC1 | |
| SCHEMBL20838886 | 0.83 | CISD2 (0.78) | ADORA1CISD2RAB9AALDH1A1NPC1 | |
| SCHEMBL20838913 | 0.83 | CISD2 (0.78) | ADORA1CISD2RAB9AALDH1A1NPC1 | |
| SCHEMBL9400304 | 0.83 | RAB9A (1.00) | ADORA1CISD2RAB9AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2908843-B1 | TREATING CANCER | AGENCY SCIENCE TECH & RES (SG) | 2019-09-04 | — | — | EP | claimed |
| US-9889180-B2 | Method of treating cancer | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2018-02-13 | — | — | US | claimed |
| US-20150258175-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-09-17 | — | — | US | claimed |
| EP-2908843-A1 | METHOD OF TREATING CANCER | Agency For Science, Technology And Research (SG) | 2015-08-26 | — | — | EP | claimed |
| WO-2014077784-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-05-22 | — | — | WO | claimed |
| US-10759774-B2 | Inhibitors of hepatitis B virus targeting capsid assembly | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759774-B2 | Inhibitors of hepatitis B virus targeting capsid assembly | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2020-09-01 | — | — | US | disclosed |
| EP-2908843-B1 | TREATING CANCER | AGENCY SCIENCE TECH & RES (SG) | 2019-09-04 | — | — | EP | disclosed |
| US-20190092742-A1 | INHIBITORS OF HEPATITIS B VIRUS TARGETING CAPSID ASSEMBLY | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-03-28 | — | — | US | disclosed |
| US-20190092742-A1 | INHIBITORS OF HEPATITIS B VIRUS TARGETING CAPSID ASSEMBLY | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2019-03-28 | — | — | US | disclosed |
| WO-2014077784-A1 | METHOD OF TREATING CANCER | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2014-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190092742-A1 | INHIBITORS OF HEPATITIS B VIRUS TARGETING CAPSID ASSEMBLY | HAVCR2, ZC3HAV1, HCCS | ADORA1 4438/4885CISD2 3262/4885RAB9A 1487/4885 |
| US-10759774-B2 | Inhibitors of hepatitis B virus targeting capsid assembly | HAVCR2, ZC3HAV1, HCCS | ADORA1 4438/4885CISD2 3262/4885RAB9A 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.